Entering China’s Intraocular Lens (IOL) Market: NMPA Registration Requirements for Foreign Manufacturers

Intraocular lens (IOL) registration in China is the gatekeeper to market access, determines whether global ophthalmic innovation can successfully translate into commercial access in the world’s second most populous country. As demand for advanced vision correction continues to grow, China has become an attractive — though tightly regulated — market for IOL manufacturers.

That demand is evident in import trends: in 2023, ophthalmology devices ranked among the top five imported medical device categories. Yet approval dynamics tell a different story. Regulatory scrutiny is high, and approvals are inconsistent: 6 IOLs were approved in 2025, while none were approved in 2024, underscoring how selective and timing-sensitive the process can be.

In this environment, product quality alone is not enough. Success hinges on a well-executed regulatory strategy, aligned with NMPA expectations from the outset.

Continue reading for a structured breakdown of the registration process, or contact Cisema for direct support with intraocular lens and other ophthalmic medical device registration in China.

Regulatory Framework for Ophthalmology Products in China

Every registration journey begins with the same foundation: understanding who regulates what, and why the bar is set where it is.

China’s National Medical Products Administration (NMPA) governs all applications for imported medical devices, including Pre-Market Approval (PMA) for Class II and III products and clinical trial authorization for high-risk devices. For imported Class II and III devices, PMA in the manufacturer’s home country is a prerequisite, not a parallel process.

For intraocular lenses, scrutiny is particularly high. As permanently implanted devices that directly affect visual outcomes, IOLs are assessed against rigorous evidence standards, with NMPA evaluations consistently focusing on:

• Product Design and Material Safety
• Non-Clinical Performance and Stability Studies
• Biocompatibility and Preclinical Safety Evaluation
• Clinical Evaluation and Labeling Compliance

This level of oversight is precisely why manufacturers who commit to China medical device registration do so with a full understanding of what’s required rather than just a general sense that it should be manageable.

That regulatory foundation, however, is itself shifting. Recent developments are reshaping what compliance will mean for IOL manufacturers in the years ahead.

Key Regulatory Developments Impacting IOL Registration in China

China’s regulatory framework is becoming more structured and enforceable, requiring manufacturers to align product-level requirements with a broader lifecycle compliance system.

These changes are interconnected. Technical guidelines define what is required for approval, while systemic reforms determine how those requirements are enforced over time.

Intraocular Lens-Specific Regulatory Guidelines in China

At the product level, the Center for Medical Device Evaluation (CMDE) has introduced targeted guidance that reduces ambiguity but increases precision in IOL registration expectations.

The 2019 “Guidelines for Clinical Trials of Intraocular Lenses” establish structured requirements for clinical study design, including defined endpoints for visual outcomes, patient selection criteria, and minimum follow-up periods. These requirements ensure that clinical evidence is both comparable and relevant to Chinese patient populations.

Building on this, the “Guidelines for Registration Review of Intraocular Lenses” issued by the CMDE in January 2022 clarify the NMPA’s core review focus:

• Material transparency: Full disclosure of material composition and formulation
• Performance validation: Robust verification of optical design and non-clinical performance
• Registration structure: Clear and compliant division of registration units

Broader Medical Device Regulatory Reforms

At the systemic level, China is transitioning from Order 739 (2021) toward a new Medical Device Administration Law. The latest draft, released in March 2025, elevates oversight to national law, introduces stricter documentation requirements, clarifies applicant obligations, and increases penalties across the full product lifecycle.

For manufacturers, this signals less flexibility and minimal tolerance for gaps. What was once an administrative oversight may now constitute a legal violation.

In parallel, updated Good Manufacturing Practice (GMP) requirements, effective November 2026, expand expectations across manufacturing and supply chain control. Key areas include:

• Responsibilities for Market Device Registration holders and filers
• Quality assurance obligations
• Digitalization expectations
• Oversight of CMOs and outsourcing

One point worth emphasizing: despite references to international alignment in the documentation, manufacturers cannot assume equivalence with ISO 13485:2016 or EU MDR 2017/745.

Penalties for non-compliance can include substantial fines, confiscation of revenue, and industry participation bans. As a result, companies planning intraocular lens registration in China must ensure their quality systems can meet these evolving requirements.

Altogether, these reforms point in the same direction: medical device registration in China is increasingly a long-term compliance commitment, not a one-time submission exercise.

Step-By-Step Intraocular Lens Registration Process in China

With both regulatory expectations and policy direction clarified, the registration pathway can be understood as a sequence of interdependent steps.

While specific requirements vary by medical device classification and available clinical data, the progression below applies to most ophthalmic medical devices that enter the Chinese market.

Step 1: Appoint a China Legal Agent

Registration in China cannot begin without a legal representative on the ground. The Legal Agent (LA) is a China-based entity that submits the application, manages NMPA communication, and oversees post-market obligations on behalf of the foreign manufacturer.

Manufacturers can establish their Legal Agent relationship through a distributor, a wholly owned local entity, or an independent service provider. Many opt for independent partners to retain control over three things that matter most:

• Control over registration certificates
• Flexibility in distributor selection
• Protection of intellectual property

This choice made early often determines how much commercial flexibility the manufacturer retains years later.

Step 2: Determine Ophthalmic Medical Device Classification

IOLs are considered Class III devices in China and require registration. Devices associated with IOLs and surgeries may require registration (Class II and III) rather than filing (Class I), which must be determined case by case.

Because misclassification can delay approval, many manufacturers conduct pre-evaluation assessments to confirm the correct pathway before preparing their dossier. Reach out to Cisema for a pre-evaluation report, or gain a deeper understanding of medical device risk classification in China in this article.

Step 3: Prepare Product Technical Requirements (PTR)

With classification confirmed, manufacturers can begin building the core technical documentation. The Product Technical Requirements document establishes the device’s:

• Performance parameters
• Material composition
• Safety requirements
• Test methods and acceptance criteria

The PTR is prepared before submission and refined throughout the registration process based on regulatory feedback. It ultimately becomes an annex to the NMPA certificate and may also support downstream commercial and post-market activities.

Step 4: Conduct Type Testing

Based on the PTR, the next step is type testing, where an NMPA-certified laboratory verifies safety and performance against Chinese standards. This stage turns written specifications into validated data.

For IOLs and related devices, China applies GB/T (general) and YY/T (medical device) standards, which do not fully align with ISO frameworks. Early alignment is therefore critical to avoid gaps or rework.

Within this framework, the “Guidelines for Registration Review of Intraocular Lenses” outline how key testing areas align with specific Chinese standards:

• Technical requirements: Defined under the YY 0290 series, covering core performance and inspection criteria
• Implantation systems: Additional requirements under YY/T 0942, even when not separately registered
• Optical performance: Evaluated according to YY 0290.2 standards for imaging quality
• Material and safety testing: Includes physicochemical and biocompatibility assessments under YY 0290.5 and GB/T 16886.1

Click here to scroll to a more detailed table of applicable standards and testing requirements.

Step 5: Conduct Clinical Evaluation and Prepare the Application Dossier

Unless exempt, Class II and III device registrations must be supported by clinical data on Chinese populations, presented within a Clinical Evaluation Report (CER).

This data may be drawn from:

• Real-World Data (RWD) from overseas or China
• Comparisons of the subject device to an already-registered predicate device
• Data generated from clinical trials within China or overseas

If one or more of the above is sufficient, new trials may not be required for class II and III devices such as IOLs for registration. Once the clinical strategy is established, the full application dossier can be compiled. This is the substantive centerpiece of the submission.

Beyond the dossier itself, manufacturers must also plan for local labelling requirements, Unique Device Identification (UDI) systems, and post-market surveillance obligations.

Costs, Timelines, and Lifecycle Management

As the process moves from preparation to execution, manufacturers must also account for practical considerations that influence planning and resource allocation.

China IOL Registration Timelines

In a well-prepared application, timelines for ophthalmology devices are relatively predictable:

• Class II devices: approximately 18 months (without new clinical trials)
• Class III devices (including intraocular lenses): approximately 21 months (without new clinical trials)

However, timelines are highly dependent on preparation quality. Misalignment with Chinese standards, incomplete testing, or gaps in clinical strategy can extend review periods significantly.

In practice, the most efficient approvals are typically those where regulatory risks are identified and resolved early in the process.

Key Cost Drivers

IOL registration costs vary with product complexity and regulatory readiness. Core expenditure areas include:

• Type testing at NMPA-certified laboratories
• Clinical evaluation and potential trial requirements
• Technical documentation and Chinese translation
• Regulatory coordination and submission management

These cost factors are interconnected. Decisions made during early stages, particularly around clinical strategy and documentation, often determine whether costs remain controlled or escalate during review.

Maintaining Compliance After NMPA Approval

Once approval is granted, the regulatory focus shifts toward maintaining market access. NMPA registration certificates are generally valid for 5 years, but ongoing compliance is required throughout the product lifecycle.

Manufacturers must manage:

• Post-market surveillance (PMS) and adverse event reporting
• Unique Device Identification (UDI) implementation
• Labeling and documentation updates
• Regulatory inspections and renewals

Companies that build these requirements into their operational systems from the outset are significantly better positioned than those who treat them as afterthoughts. Many foreign manufacturers support this transition by partnering with experienced regulatory specialists, such as Cisema, to maintain alignment between initial approval, ongoing compliance, and renewal.

6 Key Decisions for IOL Registration Success in China

Taken together, the registration journey distils into 6 key decisions that determine how smoothly and successfully foreign manufacturers navigate the NMPA medical device registration process.

Manufacturers who address these questions before submission consistently achieve more predictable outcomes. A structured pre-evaluation with an experienced regulatory partner is often the most efficient way to do so.

Final Thoughts: Achieving a Successful IOL Registration in China

China’s IOL market is growing and genuinely accessible to foreign manufacturers, but access is earned through preparation, not assumed through ambition. Because intraocular lenses are Class III devices with permanent patient impact, the NMPA applies rigorous standards to clinical evidence, technical performance, and manufacturing quality. That standard is only becoming more demanding as MDAL and updated GMP requirements take effect.

The manufacturers who succeed are those who treat China medical device registration as a strategic project with long-term compliance dimensions — not a parallel track to other market entries.

For manufacturers seeking guidance on regulatory strategy or dossier preparation, Cisema supports foreign manufacturers through the full registration and lifecycle compliance process. For a pre-evaluation report tailored to your ophthalmic device, contact Cisema today.

Further Information

• Learn more about Cisema’s China NMPA Medical Device Registration Services, including regulatory strategy and end-to-end registration support for international manufacturers.
• Explore our China Medical Device Approval Tracker for Imported Class II & III Devices for ongoing visibility into NMPA approval activity and market entry trends.
• Get a deeper understanding of classification in the China medical device risk classification guide
• Understand key terminology with our China NMPA medical device glossary

About the Author: Wesley Tucker, PhD

Wesley Tucker is the North America Sales Lead at Cisema and is based in Hong Kong and the United States. Wesley applies his background as a scientist in the Biotechnology industry toward helping foreign BioPharma and MedTech companies achieve their APAC registration and compliance goals in China and Southeast Asia.

‍

Appendix: IOL Testing Standards and Reference Table

References

• Read Cisema’s overview of the China Medical Device Administration Law (MDAL) and 2025 regulatory updates
• Review the official NMPA announcement on the Medical Device Administration Law (MDAL) draft (Chinese)
• Explore the China medical device clinical trial exemption catalog
• Access Order 739: Regulations on the Supervision and Administration of Medical Devices (English)
• Review NMPA Announcement No. 107 of 2025: Good Manufacturing Practice (GMP) for Medical Devices (English)
• Consult the Guidelines for Clinical Trials of Intraocular Lenses (2019 No. 13)
• Consult the Guidelines for Registration Review of Intraocular Lenses (2022 No. 4)

‍